Stock Price Movement and Market Context
On 23 Feb 2026, Mankind Pharma’s share price touched Rs.2014.85, its lowest level in the past year, underperforming the Pharmaceuticals & Biotechnology sector by 0.37% on the day. This decline comes despite the broader market’s positive momentum, with the Sensex rising 0.62% to close at 83,326.15 points, just 3.4% shy of its 52-week high of 86,159.02. Notably, the Sensex is trading below its 50-day moving average, though the 50DMA remains above the 200DMA, signalling mixed technical trends.
Mankind Pharma’s stock is currently trading below all key moving averages — 5-day, 20-day, 50-day, 100-day, and 200-day — indicating sustained downward pressure and a lack of short- to long-term price support. This technical weakness aligns with the stock’s underperformance relative to the Sensex, which has delivered a positive 10.64% return over the past year, whereas Mankind Pharma has declined by 12.92% during the same period.
Just made the cut! This Mid Cap from the Heavy Electrical Equipment sector entered our elite Top 1% list recently. Discover it before the crowd catches on!
- - Top-rated across platform
- - Strong price momentum
- - Near-term growth potential
Financial Performance and Valuation Metrics
Mankind Pharma’s recent financial results have been largely flat, with the half-year ended December 2025 showing limited growth. The company’s Return on Capital Employed (ROCE) for the half-year stood at 12.33%, which is the lowest recorded in recent periods and below the sector average. This contrasts with the company’s higher management efficiency indicated by a separate ROCE figure of 25.78%, suggesting some disparity in performance metrics.
Debtors turnover ratio, a key efficiency indicator, has also declined to 7.13 times for the half-year, reflecting slower collection cycles. The company’s valuation appears elevated relative to peers, with an Enterprise Value to Capital Employed ratio of 4.3, signalling a premium pricing despite subdued profit growth. Over the past year, profits have fallen by 8.1%, compounding the stock’s negative returns.
Long-Term and Relative Performance
Over a three-year horizon, Mankind Pharma has underperformed the BSE500 index, reinforcing a trend of below-par returns. The stock’s 52-week high was Rs.2726.75, indicating a significant decline of approximately 26% from that peak to the current 52-week low. This sustained underperformance has contributed to the recent downgrade in the company’s Mojo Grade from Hold to Sell as of 19 Nov 2025, with a current Mojo Score of 38.0, reflecting cautious sentiment.
Balance Sheet and Debt Metrics
Despite the challenges in earnings and price performance, Mankind Pharma maintains a strong balance sheet with a low Debt to EBITDA ratio of 0.54 times, indicating a robust capacity to service debt obligations. This financial stability is a positive aspect amid the stock’s recent price weakness.
Growth Trends and Institutional Holdings
The company has demonstrated healthy long-term growth, with net sales increasing at an annual rate of 18.21% and operating profit growing at 18.72% annually. Institutional investors hold a significant 24.59% stake in the company, reflecting confidence from entities with extensive analytical resources.
Holding Mankind Pharma Ltd from Pharmaceuticals & Biotechnology? See if there's a smarter choice! SwitchER compares it with peers and suggests superior options across market caps and sectors!
- - Peer comparison ready
- - Superior options identified
- - Cross market-cap analysis
Summary of Key Concerns
The stock’s decline to a 52-week low is underpinned by a combination of flat recent results, declining profitability, and valuation concerns. The drop below all major moving averages signals technical weakness, while the company’s underperformance relative to the Sensex and sector benchmarks highlights challenges in delivering shareholder returns. The downgrade to a Sell rating by MarketsMOJO further reflects these factors.
Positive Aspects Amidst the Decline
Nonetheless, Mankind Pharma’s strong management efficiency, low leverage, and consistent long-term sales and profit growth provide a degree of financial resilience. The sizeable institutional holding also suggests that the company retains fundamental support from knowledgeable investors.
Conclusion
Mankind Pharma Ltd’s stock reaching Rs.2014.85 marks a notable low point in its recent trading history, reflecting a period of subdued financial performance and market sentiment. While the company exhibits strengths in operational efficiency and balance sheet health, the prevailing valuation and earnings trends have contributed to its current market position.
Limited Period Only. Start at Rs. 9,999 - Get MojoOne for 1 Year + 3 Months FREE (60% Off) Get 71% Off →
